Current Role of Dacomitinib in Head and Neck Cancer.

Détails

ID Serval
serval:BIB_252EC8A01882
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Current Role of Dacomitinib in Head and Neck Cancer.
Périodique
Expert opinion on investigational drugs
Auteur(s)
Elicin O., Ozsahin M.
ISSN
1744-7658 (Electronic)
ISSN-L
1354-3784
Statut éditorial
Publié
Date de publication
06/2016
Peer-reviewed
Oui
Volume
25
Numéro
6
Pages
735-742
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) has a dismal prognosis. With the emergence of monoclonal antibodies and tyrosine kinase inhibitors (TKI) targeting the epidermal growth factor receptor (EGFR), several drugs were developed and tested in HNSCC. To date, the monoclonal antibody cetuximab is the only approved therapy for curative and recurrent/metastatic patients. Other EGFR-targeting drugs either failed in the clinical trials or are still in the early phases of drug development and research.
In this article, previously published data and ongoing studies regarding dacomitinib, a second-generation irreversible TKI, for the treatment of HNSCC are presented and discussed.
The current body of evidence is not mature enough to indicate the use of dacomitinib for the treatment of HNSCC in curative or in recurrent/metastatic settings. Phase II data suggest the potential of improved outcome in selected recurrent/metastatic HNSCC based on several biomarkers, which need to be evaluated in randomized phase III trials. Meanwhile, an ongoing phase I study is investigating dacomitinib's optimal dosing combined with and without cisplatin in the curative concomitant chemoradiotherapy setting.

Mots-clé
Animals, Antineoplastic Agents/pharmacology, Antineoplastic Agents/therapeutic use, Carcinoma, Squamous Cell/drug therapy, Carcinoma, Squamous Cell/pathology, Head and Neck Neoplasms/drug therapy, Head and Neck Neoplasms/pathology, Humans, Neoplasm Metastasis, Neoplasm Recurrence, Local, Prognosis, Protein Kinase Inhibitors/pharmacology, Protein Kinase Inhibitors/therapeutic use, Quinazolinones/pharmacology, Quinazolinones/therapeutic use, Receptor, Epidermal Growth Factor/antagonists & inhibitors
Pubmed
Création de la notice
19/04/2016 17:12
Dernière modification de la notice
20/08/2019 13:03
Données d'usage